Piper Sandler upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from an underweight rating to a neutral rating in a report issued on Tuesday morning, MarketBeat reports. Piper Sandler currently has $5.00 price objective on the stock. A number of other research firms also recently commented on MYGN. Weiss Ratings upgraded Myriad Genetics from […]

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday, Zacks reports. A number of other analysts have also recently weighed in on MYGN. Weiss Ratings raised shares of Myriad Genetics from a “sell […]

Zacks Research upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a strong sell rating to a hold rating in a report released on Thursday morning,Zacks reports. A number of other equities analysts have also recently commented on the company. Craig Hallum lifted their target price on Myriad Genetics from $4.00 to $8.00 and […]